ArticleTherapeutic advances in musculoskeletal disease2025
Distinctive clinical patterns and management trends in late-onset psoriatic arthritis: data from Argentina's RECCAPSO registry.
Article in Therapeutic advances in musculoskeletal disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Complex-to-manage and treatment-refractory psoriatic arthritis in Argentina: real-world evidence from the RECCAPSO network.Clinical rheumatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Late-onset psoriatic arthritis (LO-PsA) has been underexplored despite its growing prevalence in aging populations. Understanding its distinct clinical presentation and treatment patterns is essential to optimize care in this subgroup. Objectives: To describe the demographic, clinical, and therapeutic features of patients with LO-PsA compared to early onset PsA (EO-PsA) using data from the Argentine RECCAPSO registry. Design: Ambispective, multicenter analysis with a cross-sectional evaluation. Methods: Patients with PsA were categorized into EO-PsA (age of onset ⩽60 years) and LO-PsA (>60 years). Demographics, clinical characteristics, disease activity, and treatment variables were compared between groups using appropriate statistical tests. A multivariate logistic regression model was constructed to identify factors independently associated with LO-PsA. Results: A total of 271 PsA patients were included (EO-PsA: Conclusion: LO-PsA presents a distinct clinical profile characterized by greater comorbidity burden and lower exposure to advanced therapies. These findings highlight the need for tailored management strategies in older adults with PsA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.